IMVAMUNE (MVA-BN)

BIOLOGICAL4 trials

Sponsors

Bavarian Nordic

Conditions

Dermatitis, AtopicHIV InfectionsHay FeverSmallpox

Phase 1

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

CompletedNCT00189904

Bavarian NordicHIV Infections

Start: 2005-07-31Updated: 2012-09-28

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

CompletedNCT00189917

Bavarian NordicDermatitis, Atopic, Hay Fever

Start: 2004-04-30Updated: 2019-01-10

Phase 2

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

CompletedNCT00189956

Bavarian NordicSmallpox

Start: 2003-04-30End: 2005-12-31Updated: 2019-01-10

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

CompletedNCT00316589

Bavarian NordicHIV Infections

Start: 2006-06-30End: 2009-10-31Updated: 2019-01-03

Related Papers

Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.

2014-08-2042 citations